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Abstract: Ankle brachial index (ABI) has been utilized in the management of peripheral arterial disease (PAD).ABI is a 
surrogate marker of atherosclerosis and recent studies indicate its utility as a predictor of future cardiovascular disease and
all-cause mortality. Even so, this critical test is underutilized. The purpose of this review is to summarize available evi-
dence associated with ABI methodology variances, ABI usage in the treatment of PAD, and ABI efficacy in predicting 
cardiovascular disease. This review further evaluates how ABI is used in the prognosis and follow-up of lower extremity 
arterial disease.We reviewed the most current American College of Cardiology guidelines for the management of PAD, 
the Trans Atlantic Intersociety Consensus (TASC) working group recommendations, and searched the Medline for the fol-
lowing words: ankle brachial index, ABI sensitivity and specificity, and peripheral arterial disease.  
The ABI is a simple, noninvasive clinical test that should not only be applied to diagnose PAD, but also to provide impor-
tant prognostic information about future cardiovascular events. Although the ABI has been employed in clinical practice 
for some time, our review of various studies reveals a lack of standardization regarding both the method of measuring ABI 
and the cutoff point for abnormal ABI. It is extremely important that we understand all aspects of this crucial test, as it is 
now being recommended as part of a patient’s routine health risk assessment.  
Key Words: Peripheral arterial disease, Ankle Brachial index, ABI Sensitivity and Specificity, Atherosclerosis, Cardiovascular 
morbidity and mortality. 
INTRODUCTION 
  Peripheral arterial disease (PAD) of the lower extremities 
is a common disease affecting approximately 12 million 
people in the United States [1]. Atherosclerosis is the major 
cause of PAD of lower extremities [2]. The prevalence of 
PAD varies based on the population surveyed and the meth-
odology of computing the ankle-brachial index (ABI) [3-5].  
The ABI is the preferred initial screening test to help diag-
nose and grade the obstruction of peripheral arterial disease 
(PAD) in the legs. Interval ABI results are used to monitor 
the efficacy of revascularization procedures of lower ex-
tremities. Additional uses of ABI include predicting the 
prognosis regarding the limb salvage, wound healing and 
future cardiovascular related morbidity and mortality [6].
HISTORICAL PERSPECTIVE 
  Arterial measurements in lower extremities were first 
described by Naumann in 1930 [7].  In 1950,Winsor was 
first to use ABI measurements in patients with peripheral 
arterial disease [8].  
METHODS OF MEASURING ANKLE BRACHIAL 
INDEX 
  The measurement of the ABI involves recording the sys-
tolic pressures in the brachial artery at each elbow and sys-
tolic pressures in the posterior tibial and the dorsalis pedis 
arteries at each ankle. The result is reported as a ratio of the 
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ankle systolic pressure in the numerator,over the higher bra-
chial pressure in the denominator. The ABI is calculated for 
each leg separately, and the lower of the two values is taken 
as a result for the patient. Numerous methods of calculating 
the ABI have been described based with variances in the 
numerator taken in the ABI equation: 
a) The current method recommended by the ACC/AHA in-
volves using the higher of the two ankle systolic arterial 
pressures, termed high ankle pressure (HAP) (Fig. 1) as the 
numerator in the ABI equation [2,6,9-12].
b) A second method reported in the literature uses the lower 
of the two ankle systolic arterial pressures,termed low ankle 
pressure (LAP) as the numerator when calculating the ABI 
[5,13,14]. 
c) A calculation applied in some epidemiological studies 
uses the average of the two ankle systolic pressures as the 
numerator in the ABI equation [15,16]. 
d) A few studies have used the posterior tibial artery systolic 
pressure to calculate ABI [17,18]. 
INTERPRETATION OF ABI RESULTS
  The patient is diagnosed with PAD when the ABI is < 0.9 
[2,19]. PAD is graded as mild to moderate if the ABI is be-
tween 0.4 and 0.9, and an ABI less than 0.40 is suggestive of 
severe PAD [19]. An ABI value greater than 1.3 is also con-
sidered abnormal, suggestive of non-compressible vessels. 
CORRELATION OF ABI WITH LOWER EXTREM-
ITY FUNCTION AND OUTCOMES 
  Patients with mild to moderate PAD are likely to experi-
ence lower extremity pain with exercise (claudication). Pa-102 Current Cardiology Reviews, 2008, Vol. 4, No. 2 Khan et al. 
tients with ABI less or equal to 0.5 are likely to have lower 
extremity pain while resting [20]. Criqui et al. reported that 
the incidence of claudication (applying Rose criteria) was 49 
% in patients with ABI < 0.6 compared to 34 % in patients 
with ABI between 0.6 and < 0.9 [21]. 
  Several specific ABI values indicate evidence of correla-
tion with the leg function in multiple studies. In a study of 
865 women aged 65 and older, McDermott et al. discovered 
that subjects with ABI < 0.6 were at higher risk of having 
impaired walking abilities [13]. In an earlier study McDer-
mott et al. [22] reported that among patients with PAD, de-
creases in ABI values are associated with decreases in six 
minute walk distance, maximum walking speed, and walking 
endurance. Each increase of 0.4 in the ABI was associated 
with an increase in the six minute walk distance and usual 
and maximal walking speed. 
  An ABI <0.4 increases the risk of limb loss, gangrene, 
ulceration and delayed wound healing [6,23]. However, an 
absolute ankle systolic pressure less than 60 mmHg, rather 
than the ABI value, has been found to correlate better in 
terms of viability of the lower extremities in PAD [2,24]. 
SENSITIVITY AND SPECIFICITY OF THE ABI IN 
THE DIAGNOSIS OF PAD 
  Numerous studies have reported that the ABI, when 
compared to angiography, has a sensitivity of more than 90% 
and a specificity of more than 95% in diagnosing 50% steno-
sis of the lower extremity arteries [6,11,12,16,17,25,26].
However, Schroder et al. recently reported that the HAP ABI 
had a sensitivity of 68% and a specificity of 99% [27]. The 
authors reported the LAP ABI sensitivity and specificity to 
be 89 and 93% respectively. Niazi et al. reported that the 
HAP ABI had a sensitivity of 69% with a specificity of 83%. 
The sensitivity and specificity of the LAP ABI was 84% and 
64% respectively [28].
 Feigelson  et al. [29] evaluated the sensitivity of an ABI < 
0.8 to be 39 % within the entire cohort and 70% in patients 
with PAD (This study is reported by ACC/AHA guidelines 
that ABI has a sensitivity of 89% in diagnosing PAD).  Li-
jmer et al. has reported that an ABI value of 0.91 had a sen-
sitivity of 79% and a specificity of 96% to detect 50% or 
more stenosis of lower extremity arteries defined on angi-
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ography [30]. Angiograms of the lower extremities were 
available for only 53 patients (12% of the total patients in 
study). Stoffers et al. applied ROC analysis and reported the 
sensitivity and specificity for ABI < 0.97 to be 79% and 82% 
respectively [31]. When two vascular technicians using ul-
trasound technology interpreted the ankle arterial pulse wave 
forms as “pathologic”, the diagnosis of PAD was deter-
mined. No angiographic confirmation for the diagnosis of 
PAD was provided. 
  Based on the evaluated studies, we find that the lower 
ankle pressure ABI has better sensitivity in diagnosing PAD. 
Additionally, the context in which few studies [24,32-34] are 
reported (that ABI has been shown to be > 90% sensitive and 
> 95% specific to diagnose 50% stenosis of lower arteries) is 
inaccurate. Carter and Yao [32,33] only concluded that ABI 
was low in patients with PAD without providing any ABI 
sensitivities. Ouriel did report in his two studies [23,34] that 
ABI < 0.97 has a sensitivity of more than 97% and specific-
ity of more than 100% respectively in diagnosing PAD. 
Nevertheless, the lack of the authors definition of PAD in 
terms of diameter stenosis of the arteries weakens the valida-
tion of their findings.  
ROLE OF THE ABI IN THE FOLLOW UP OF PAD 
PATIENTS AFTER LOWER EXTREMITY INTER-
VENTION 
 Mclafferty  et al. reported the sensitivity and specificity of 
ABI to detect the progression of lower extremity arterial 
disease after surgical intervention [35].  One hundred four-
teen patients (193 Limbs) were followed for a mean of 3.3 
years. A baseline ABI was established for each patient, fol-
lowed by another ABI within a week of the revascularization 
procedure. Progression of the PAD was documented with 
arterial duplex scanning or arteriography of the lower ex-
tremities if clinically indicated. Disease progression was 
only monitored in native arteries and not in the bypass grafts. 
The authors reported that a drop of the ABI more than 0.15 
carried a sensitivity of 41% and a specificity of 84% to de-
tect the progression of lower extremity arterial disease.  
 Decrinis  et al. tested the sensitivity and specificity of 
ABI in patients who had undergone angioplasty of the super-
ficial femoral artery stenosis [36]. ABI were performed post-
operative day one, three, six and twelve months after the 
procedure. Follow up angiograms of the lower extremities 
were performed one year after angioplasty. A total of 116 
patients were enrolled in the study. (Angiographic definition 
of re-stenosis was progression of post PTA 50% stenosis to 
more than 70% at follow up angiogram or an increase in the 
stenosis severity to 10 % or more of predilation obstruction.) 
For an ABI drop of 0.10 the sensitivity and specificity were 
72% and 82% respectively in predicting restenosis using 
their criteria. An ABI drop of 0.15 had a sensitivity and 
specificity of 66% and 100% respectively for restenosis. In 
predicting the patency of the post PTA vessel, an improve-
ment of ABI of 0.10 post PTA had sensitivity and specificity 
of 79 % and 92%. ABI improvement of 0.15 post PTA had 
sensitivity and specificity of 67% and 100% respectively for 
patency of post PTA artery.  
ABNORMAL ABI AS MARKER OF ATHEROSCLE-
ROSIS AND PREDICTOR OF FUTURE CARDIO-
VASCULAR MORBIDITY AND MORTALITY 
  The unique role that ABI plays as a marker of atheroscle-
rosis is clear by its correlation with cardiovascular disease 
(CVD) in multiple population based studies [9-18].  The 
measurement of ABI has been recommended as part of risk 
assessment and primary prevention of CVD in asymptomatic 
individuals who have intermediate risk factors for CVD 
[37,38].  There is consensus that an abnormal ABI in an oth-
erwise asymptomatic individual would categorize him in the 
high risk category for future CVD. The American Diabetes 
Association recommends routinely screening all patients 
with diabetes above age 50 and in all diabetics with risk fac-
tors (e.g. smoking, hyperlipidemia etc) for PAD under age 
50 [39].  
1) Cardiovascular Disease (CVD) and Mortality 
  Numerous epidemiologic studies have reported up to four 
fold increased rates of cardiovascular disease and mortality 
with abnormal ABI [9-18,40-49]. Findings of some of these 
are summarized in Table 1.
 Vogt  et al. reported that the mortality rates from athero-
sclerotic heart disease doubled (RR 2.0 95% CI 1.4-2.9) with 
each 0.5 units drop in the ABI [16].  The ten year mortality 
rates of CVD in patients with an ABI < 0.5 was 37%, com-
pared to a 27 % in patients with ABI values ranging between 
0.5- 0.7, 22 % in patients with ABI 0.7- 0.9 and 17 % in pa-
tients with ABI values >0.9(P=0.0039). Relative risk for all 
cause mortality was higher (1.95, 95% CI 1.42-2.68) in sub-
jects with ABI < 0.5 compared to subjects with ABI values 
ranging between 0.51-0.7 (RR 1.59, 95% CI 1.18-2.15). 
 O’Hare  et al. investigated the rates of cardiovascular dis-
ease and mortality across different levels of ABI [40]. The 
cohort included 5748 subjects, their mean age was 73 years, 
and the mean follow-up was 11 years. The study found that 
subjects with an ABI < 0.6 was consistently associated with 
increased CV mortality (hazard ratio [HR] 2.13 95%,CI 
1.49-30.5), all cause mortality (HR 1.82,95%CI 1.42-2.32) 
and cardiovascular events(HR 1.60,95% CI 1.09-2.34) com-
pared to participants with ABI 1.10-1.20. In the Framingham 
Offspring study the prevalence of CAD was 30% in patients 
with an ABI < 0.9 compared to 10% in subjects with ABI 
>1.0 (P 0.001) [41]. Among the participants of the HOPE 
trial, the percent rates of CV disease, CV death and all cause 
mortality in subjects with an ABI >0.9 were 10.1,5.3 and 8.8 
respectively, compared to 13.7, 8.6,12.8 in the ABI group 
0.6-0.9, and 13.4, 9.4 and 14.7 in the ABI group < 0.6 re-
spectively [42].  
2) Risk for Stroke / Transient Ischemic Attack (TIA) 
 Zheng  et al. reported that the risk of Stroke /TIA for men 
with ABI < 0.9 was four times (Odds Ratio 4.2 -4.9, 95% CI 
1.8-9.5) than in those with an ABI >0.9 [43]. In the 
Framingham study, the risk of stroke/ TIA was two fold 
(Hazards ratio 2.0, 95% CI 1.1-3.7) among participants with 
an ABI< 0.9 [15].  In the Framingham offspring study the 
prevalence of stoke was 9% in men with ABI< 0.9 compared  104 Current Cardiology Reviews, 2008, Vol. 4, No. 2 Khan et al. 
to 2 % in men with ABI > 1.0 (0.001) [41]. In the Cardiovas-
cular Health Study, patients with ABI <0.8 had twice the 
rates of stroke/TIA [44].  Similarly, Leng et al. reported that 
subjects with an ABI <0.9 had increased risk of stroke(RR 
1.98, 95% CI 1.05-3.77) [45]. 
  In a meta analysis of nine studies Doobay reported the 
predictive value of ABI in predicting future cardiovascular 
events [46]. The authors reported that an ABI less than 0.9 
has a sensitivity and specificity of 16.55 and 92.7% for CAD 
(likelihood ratio 2.53), 16.0% and 92.2% for stroke (likeli-
hood ratio 2.45) and 41.0% and 87.9% for cardiovascular 
mortality (likelihood ratio 5.61), respectively.  
 Heald  et al. performed a systematic review of 11 pub-
lished studies with a combined number of 44590 subjects 
[47].Theauthors reported that ABI < 0.9 was associated with 
increased all cause mortality (RR 2.35, P< 0.001), cardiovas-
cular and cerebrovascular mortality (RR 2.34, P =0.002), 
fatal and non-fatal coronary heart disease (RR 2.13, P= 
0.003) and fatal and non-fatal stroke (RR 1.86, P=0.07).  
  An ABI < 0.9 identifies subjects with increased future 
cardiovascular morbidity and mortality. However, across the 
range of ABI a value < 0.6 has been found with increased 
CV events (Table 1).  
3) Abnormal ABI as Predictor of Morbidity and Mortal-
ity in Post-Coronary Artery Bypass Graft Patients 
  Abnormal ABI has been found as prognostic indicator for 
survival and complications among patients undergoing coro-
nary artery bypass surgery. Aboyans V et al. studied the role 
of abnormal ABI as a marker for long term prognosis in the 
post coronary artery bypass graft patients (CABG) [48]. The 
mean age of the patients was 69 years with a follow-up of 
4.4 years. Patients with clinical PAD (defined as history of 
vascular surgery and/or history of intermittent claudication) 
and sub clinical PAD (defined as ABI<0.85) had three fold 
excess risk of primary end points (composite of cardiovascu-
lar death, non-fatal acute coronary syndrome, non-fatal 
stroke, TIA and coronary or peripheral revascularization) 
compared to patients without PAD after CABG. Risk of 
acute coronary syndrome was more than two times (HR 2.12 
to 2.35) in patients with clinical and sub clinical PAD.  
 Burek  et al. studied the five year mortality rates in Post 
CABG/ Coronary PTCA patients. The five year mortality 
Table 1.  Cardiovascular, Stroke / TIA and All Cause Mortality Across Range of ABI in Published Studies 
Study  No Study Sub-
jects 
 ABI  Effect Measure  CVD  CVD Mortality  All Cause Mor-
tality 
Stroke/ TIA 
Diehm et al. 12  6880  < 0.9  Odds Ratio   1.53  N/A  N/A  1.77 
Vogt  et al.
16
1930 >0.9 
<0.9-0.71 
<0.7-0.51 
<0.50  
Relative 
Risk  
  N/A  RR 2.0 each  
< 0.5 Drop in  
ABI. 
1.0 
1.15-0.95 
1.59-1.70 
1.95-2.13 
 No Significant 
association 
O’Hare et al.
40
5748 0.91-1.0 
0.81-0.90 
0.71-0.81 
0.61-0.70 
<0.61 
Hazard  
Ratio 
1.37 
1.72 
1.63 
1.57 
1.60 
1.60 
2.37 
2.01 
2.31 
2.13 
1.40 
1.73 
1.80 
2.08 
1.82 
Included in 
CVD. 
 Ostergen 
et al. 42 
8986 >  0.9 
0.9-0.6 
<0.6 
Four year  
Clinical out-
comes 
(Percent rates). 
10.1 
13.7 
13.4  
P 0.0038 
5.3 
8.6 
9.4 
P <0.0001 
8.8 
12.8 
14.7 
P .0002 
3.5 
4.3 
5.9 
P 0.234 
Zheng et al.
43
15106 <0.9 
0.91-1.0 
Odds Ratio  4.5  
(P<0.05) 
2.4 
 N/A  N/A  4.3 
(P <.001) 
1.7 
Leng et al.
45
1592 1.0-0.9 
0.9-0.71 
<0.7 
 Five Year 
Incidence 
5% 
7% 
9% 
P.057 
6% 
8% 
21% 
P <.001 
 11% 
16% 
34%  
P <.001 
3% 
3% 
3% 
P .020 
N/A: Data not provided; CVD: Cardiovascular Disease; TIA: Transient Ischemic attack. Critical Review of the Ankle Brachial Index  Current Cardiology Reviews, 2008, Vol. 4, No. 2    105
rate was 14 % in patients with ABI < 0.9 compared to 3% in 
patients with ABI > 0.9 (RR 4.9 95% CI 1.8-13.4, P 0.001) 
[49]. The investigators reported that abnormal ABI< 0.9 was 
a strong predictor of mortality among patients with multives-
sel CAD. 
CONCLUSION 
  We conclude that ABI is the screening test of choice for 
the diagnosis of patients with PAD due its simplicity, repro-
ducibility and cost effectiveness. Recent studies suggest the 
use of low ankle pressure ABI as the method for calculating 
the ABI due to its better sensitivity. Use of ABI is recom-
mended as part of management of patients who have under-
gone lower extremity revascularization procedures. 
  As surrogate marker for atherosclerosis, ABI has been 
found to give very important prognostic information regard-
ing future cardiovascular events. We notice different meth-
ods and cutoff points for abnormal ABI have been used in 
different epidemiologic studies. There is a need for a uni-
form method of ABI to be used in studies. Current evidence 
suggests the use of ABI for identifying high risk patients for 
future cardiovascular and cerebrovascular mortality. In doing 
so, one can aggressively modify risk factors to prevent both 
short and long term events. 
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